Study analysis · Diabetes · 2023
This drug burns fat and builds muscle—without you dieting or exercising.
A shot called bimagrumab made people lose over 20% of their body fat and gain muscle, even when they ate the same amount of food.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study shows that when people with obesity and diabetes took this new medicine, they lost fat and gained muscle—even without eating less. But it doesn't prove the medicine caused it for sure, because we don't know if everyone was kept unaware of who got the real drug.
What’s the bottom line?
This study tested a new medicine that tricks the body into burning fat and building muscle, even if you eat the same amount.
How strong is this study?
The study is pretty good because it randomly gave some people the medicine and others a fake pill, which helps us know if the medicine really worked. But it's not perfect because we don't know if the doctors and patients knew who got what, and only 75 people were in it, so we can't be sure it works for everyone.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
64 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 570 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, blinding is unknown, which introduces potential performance and detection bias. However, randomization and a control group allow for causal inference, albeit with moderate confidence due to lack of blinding confirmation.
Major COI
Major conflicts that significantly reduce study credibility
Bimagrumab study authors have significant financial ties to Versanis Bio, the company developing the drug being tested, including employment and consulting roles, raising concerns about bias in study design and interpretation.
Funders
Conflict Details
Versanis Bio: Employee
Versanis Bio: Consultant
Novartis AG: Stock/Shareholder
Alcon Research, LLC: Stock/Shareholder
Novo Nordisk A/S: Stock/Shareholder
No funding statement is provided, but the presence of an employee of Versanis Bio as a lead author and a consultant with financial stakes in competing pharmaceutical companies creates a high risk of bias. The study's conclusions favor bimagrumab's efficacy without independent verification of analysis methods.
Key takeaways
- 01
Fat dropped by 22.2%, muscle went up by 3.6%, belly fat dropped by 36.1%, liver fat dropped by 23.6%, and blood sugar improved — all without eating less.
- 02
Losing over 20% of body fat and gaining muscle without dieting or exercise is a big deal — it could mean better health and longer-lasting weight loss than current drugs.
Surprising findings
- Bimagrumab improved HbA1c by 0.76% without reducing calories, while placebo HbA1c increased by 0.04%.Typically, blood sugar improvements from weight loss are tied to reduced food intake—here, metabolic health improved purely from fat loss and muscle gain.
- Liver fat dropped by 23.6% in just 24 weeks without dietary changes.Non-alcoholic fatty liver disease (NAFLD) is usually treated with diet and exercise—this drug reversed it pharmacologically, which was thought to be nearly impossible without lifestyle change.
Practical takeaways
If you're struggling with weight regain after dieting, ask your doctor about emerging body composition drugs like bimagrumab—especially if you have type 2 diabetes or fatty liver.
This drug is not yet approved; it's still in trials. Side effects like diarrhea and muscle spasms were common in IV form, and long-term safety is unknown.
medium confidenceTrack your body composition (not just weight)—if you're losing muscle while losing fat, you might benefit from future drugs that target muscle preservation.
Current methods like DXA scans are expensive and not routine. Focus on strength training and protein intake now as the best available alternative.
high confidenceWhy this study matters
Fat Loss Without Dieting
Bimagrumab reduced total body fat by 22.2% and visceral fat by 36.1% over 48 weeks, with no significant change in caloric intake. This means the drug directly altered fat metabolism, not appetite.
Most weight-loss drugs work by making you eat less—this one works by rewiring how your body stores and burns fat, which could revolutionize obesity treatment.
Muscle Gain While Losing Fat
Participants gained 3.6% more lean mass (1.7 kg) while losing fat—unlike most weight-loss drugs that cause muscle loss. Liver fat dropped 23.6% and paravertebral muscle mass increased by 6.4%.
Losing fat while gaining muscle is the holy grail of body recomposition—this drug does it without exercise, which could help elderly or mobility-limited patients.
The Subcutaneous Shot That Works Just as Well
A lower-dose, self-injected version (525 mg SC every 4 weeks) produced similar fat loss and muscle gain as the IV version, but with fewer side effects like diarrhea and muscle spasms.
If approved, this could become a home-based treatment like insulin—no clinic visits needed, making it far more accessible and scalable.
Effects Last After Stopping
Fat loss was maintained for at least 12 weeks after the last dose, suggesting the changes aren't just temporary while on the drug.
Most weight-loss drugs lead to rapid regain after stopping—this one might offer lasting results, which is rare and valuable.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new medicine that tricks the body into burning fat and building muscle, even if you eat the same amount.
Research results
Fat dropped by 22.2%, muscle went up by 3.6%, belly fat dropped by 36.1%, liver fat dropped by 23.6%, and blood sugar improved — all without eating less.
What this means - more context
Losing over 20% of body fat and gaining muscle without dieting or exercise is a big deal — it could mean better health and longer-lasting weight loss than current drugs.
This study evaluates whether bimagrumab, a myostatin/activin blocker, can reduce fat and increase lean mass in adults with obesity and type 2 diabetes without relying on appetite suppression.
Bimagrumab significantly reduced total body fat mass by 22.2% and increased lean mass by 3.6% over 48 weeks in adults with obesity and type 2 diabetes, despite no meaningful change in caloric intake. It also reduced visceral fat by 36.1% and liver fat by 23.6%, improved HbA1c by 0.76%, and showed durable effects 12 weeks post-treatment. Subcutaneous dosing produced similar results with fewer side effects.
Methods Used
Phase 2 randomized, placebo-controlled trial (N=75) with adults with obesity and type 2 diabetes; participants received weekly IV bimagrumab (10 mg/kg) or placebo for 48 weeks. Body composition was measured by DXA and MRI; glycemic control was assessed via HbA1c. A Phase 1 trial compared IV and subcutaneous dosing.
Main Finding
Bimagrumab reduced total body fat mass by 22.2% and increased lean mass by 3.6% over 48 weeks, independent of caloric intake, while also reducing visceral fat by 36.1% and hepatic fat by 23.6%, and improving HbA1c by 0.76% compared to placebo.
Confidence Level
High — randomized, placebo-controlled trial with objective imaging (DXA/MRI) and statistically significant outcomes (p<0.001 for primary endpoints), with effect sizes reported.
Study Flags
Red Flags
- •Small sample size (N=75)
- •Short follow-up beyond treatment (12 weeks post-dose)
- •Industry-funded with author financial ties to manufacturer
Surprising Findings
Bimagrumab improved HbA1c by 0.76% without reducing calories, while placebo HbA1c increased by 0.04%.
Typically, blood sugar improvements from weight loss are tied to reduced food intake—here, metabolic health improved purely from fat loss and muscle gain.
Practical Takeaways
If you're struggling with weight regain after dieting, ask your doctor about emerging body composition drugs like bimagrumab—especially if you have type 2 diabetes or fatty liver.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 570 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study shows that when people with obesity and diabetes took this new medicine, they lost fat and gained muscle—even without eating less. But it doesn't prove the medicine caused it for sure, because we don't know if everyone was kept unaware of who got the real drug.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized controlled design
- Use of objective measures (DXA, MRI)
- Placebo-controlled comparison
Weaknesses
- Blinding status unknown
- Small sample size limiting statistical power
- Short duration of follow-up
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new medicine that tricks the body into burning fat and building muscle, even if you eat the same amount.
Research results
Fat dropped by 22.2%, muscle went up by 3.6%, belly fat dropped by 36.1%, liver fat dropped by 23.6%, and blood sugar improved — all without eating less.
What this means - more context
Losing over 20% of body fat and gaining muscle without dieting or exercise is a big deal — it could mean better health and longer-lasting weight loss than current drugs.
This study evaluates whether bimagrumab, a myostatin/activin blocker, can reduce fat and increase lean mass in adults with obesity and type 2 diabetes without relying on appetite suppression.
Bimagrumab significantly reduced total body fat mass by 22.2% and increased lean mass by 3.6% over 48 weeks in adults with obesity and type 2 diabetes, despite no meaningful change in caloric intake. It also reduced visceral fat by 36.1% and liver fat by 23.6%, improved HbA1c by 0.76%, and showed durable effects 12 weeks post-treatment. Subcutaneous dosing produced similar results with fewer side effects.
Methods Used
Phase 2 randomized, placebo-controlled trial (N=75) with adults with obesity and type 2 diabetes; participants received weekly IV bimagrumab (10 mg/kg) or placebo for 48 weeks. Body composition was measured by DXA and MRI; glycemic control was assessed via HbA1c. A Phase 1 trial compared IV and subcutaneous dosing.
Main Finding
Bimagrumab reduced total body fat mass by 22.2% and increased lean mass by 3.6% over 48 weeks, independent of caloric intake, while also reducing visceral fat by 36.1% and hepatic fat by 23.6%, and improving HbA1c by 0.76% compared to placebo.
Confidence Level
High — randomized, placebo-controlled trial with objective imaging (DXA/MRI) and statistically significant outcomes (p<0.001 for primary endpoints), with effect sizes reported.
Study Flags
Red Flags
- •Small sample size (N=75)
- •Short follow-up beyond treatment (12 weeks post-dose)
- •Industry-funded with author financial ties to manufacturer
Surprising Findings
Bimagrumab improved HbA1c by 0.76% without reducing calories, while placebo HbA1c increased by 0.04%.
Typically, blood sugar improvements from weight loss are tied to reduced food intake—here, metabolic health improved purely from fat loss and muscle gain.
Practical Takeaways
If you're struggling with weight regain after dieting, ask your doctor about emerging body composition drugs like bimagrumab—especially if you have type 2 diabetes or fatty liver.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 570 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study shows that when people with obesity and diabetes took this new medicine, they lost fat and gained muscle—even without eating less. But it doesn't prove the medicine caused it for sure, because we don't know if everyone was kept unaware of who got the real drug.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized controlled design
- Use of objective measures (DXA, MRI)
- Placebo-controlled comparison
Weaknesses
- Blinding status unknown
- Small sample size limiting statistical power
- Short duration of follow-up
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is pretty good because it randomly gave some people the medicine and others a fake pill, which helps us know if the medicine really worked. But it's not perfect because we don't know if the doctors and patients knew who got what, and only 75 people were in it, so we can't be sure it works for everyone.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
64 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 570 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, blinding is unknown, which introduces potential performance and detection bias. However, randomization and a control group allow for causal inference, albeit with moderate confidence due to lack of blinding confirmation.
Major COI
Major conflicts that significantly reduce study credibility
Bimagrumab study authors have significant financial ties to Versanis Bio, the company developing the drug being tested, including employment and consulting roles, raising concerns about bias in study design and interpretation.
Funders
Conflict Details
Versanis Bio: Employee
Versanis Bio: Consultant
Novartis AG: Stock/Shareholder
Alcon Research, LLC: Stock/Shareholder
Novo Nordisk A/S: Stock/Shareholder
No funding statement is provided, but the presence of an employee of Versanis Bio as a lead author and a consultant with financial stakes in competing pharmaceutical companies creates a high risk of bias. The study's conclusions favor bimagrumab's efficacy without independent verification of analysis methods.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence